目的 研究依达拉奉(edaravone)对严重烧伤手术患者多脏器保护的安全性和有效性。方法 严重烧伤手术患者60例，ASAⅡ～Ⅲ级，随机分为依达拉奉组(E组)和生理盐水对照组(C组)，每组30例。采用静吸复合全身麻醉。E组患者在麻醉诱导完成后静脉泵入依达拉奉60 mg，C组泵入生理盐水40 ml;先以40 ml/h速度泵入30 min，然后以10 ml/h速度泵入其余药量。监测记录患者生命体征，并于麻醉前(T₁)、手术1 h(T₂)、术毕(T₃)、术后24 h(T₄)4个时点抽取静脉血，检测各时点的肝肾功能、血清SOD、MDA、S-100b、NSE、cTnI、BNP等指标。结果 在术毕及术后24 h时点，E组患者的cTnI较基础值、C组均显著降低(P<0.01)，C组患者较基础值显著升高(P<0.01);在术后1 h及术毕时点，E组患者的MDA较基础值、C组均显著降低(P<0.01)，C组患者较基础值显著升高(P<0.01);在术后1 h及术毕时点，E组患者的SOD较基础值明显升高(P<0.05)、较C组均显著升高(P<0.01)，两组患者在术后24 h均较基础值显著降低(P<0.01);两组患者BNP、NSE各时点比较差异无统计学意义(P>0.05);两组患者肝肾功能比较差异无统计学意义(P>0.05)。结论 依达拉奉持续输注用于严重烧伤患者手术，可有效降低心肌损伤和氧自由基损伤，可抑制心力衰竭和脑损伤，不影响肝肾功能，且无不良反应，是一种安全可靠、效果确切的脏器保护药物。

Objective To study the effect of edaravone on multiple organ protection in operation of the patients burned severely. Methods Sixty patients burned severely, ASA grade Ⅱ-Ⅲ, were randomly divided into edaravone group (group E) and saline control group (group C). 30 cases in each group. General anesthesia was used. Patients in group E were injected with 60mg (40ml) of edaravone, and patients in group C with saline 40ml.At the first 30min, 40ml/h speed infusion, and then 10 ml/h. Patient’s vital signs were onitored. The functions of liver and kidneys and the serum concentrations of SOD, MDA, S-100b, NSE, cTnI, BNP were etected at this times: before anesthesia (T₁), 1h after operation (T₂), the end of operation (T₃), 24h after operation (T₄). Results At T₃ and T₄, compared with the basic value and group C, cTnI of patients in group E significantly decreased (P<0.01); compared with the basic value, cTnI of patients in group C increased significantly (P<0.01). At T₂ and T₃, compared with the basic value, MDA of patients in group E was significantly reduced(P<0.01), but increased significantly in the group C(P<0.01). At T₂ and T₃, compared with the basic value, SOD of patients in group E was increased significantly (P<0.05);and compared with group C, it was increased significantly (P<0.01). There were no significant differences between the two groups in BNP, NSE at different time points (P>0.05). There was no significant difference between the two groups in liver and kidney functions (P>0.05). Conclusions In the operation of patients severely burned, edaravone effectively reduces the myocardial injury and the injury of oxygen free radicals, inhibits heart failure and brain damage, does not affect the function of liver and kidney, and has no adverse reactions. It is a safe and reliable protective drug.